New insights into the autotaxin/LPA axis in cancer development and metastasis

Experimental Cell Research

Volumn 333, Issue 2, 2015, Pages 183-189

  Leblanc, Raphaël ^a   Peyruchaud, Olivier ^a  

^a INSERM   (France)

Author keywords

ATX; Autotaxin; Cancer; LPA; Lysophosphatidic acid; LysoPLD; Metastasis

Indexed keywords

AUTOTAXIN; LYSOPHOSPHATIDIC ACID; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHOLIPID; PHOSPHODIESTERASE;

ANGIOGENESIS; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; HUMAN; METASTASIS; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSGENIC ANIMAL; TUMOR CELL; TUMOR INVASION; ANIMAL; BONE TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SECONDARY; SIGNAL TRANSDUCTION;

ANIMALIA;

ANIMALS; BONE NEOPLASMS; CARCINOGENESIS; HUMANS; LYSOPHOSPHOLIPIDS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORIC DIESTER HYDROLASES; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION;

EID: 84927913438     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.11.010     Document Type: Review

References (68)

1. Merchant T.E., Kasimos J.N., de Graaf P.W., Minsky B.D., Gierke L.W., Glonek T. Phospholipid profiles of human colon cancer using 31P magnetic resonance spectroscopy. Int. J. Colorectal Dis. 1991, 6:121-126.
2. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3:582-591.
3. Sasagawa T., Okita M., Murakami J., Kato T., Watanabe A. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 1999, 34:17-21.
4. Baker D.L., Morrison P., Miller B., Riely C.A., Tolley B., Westermann A.M., Bonfrer J.M., Bais E., Moolenaar W.H., Tigyi G. Plasma lysophosphatidic acid concentration and ovarian cancer. J. Am. Med. Assoc. 2002, 287:3081-3082.
5. Eder A.M., Sasagawa T., Mao M., Aoki J., Mills G.B. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer Res. 2000, 6:2482-2491.
6. Furui T., LaPushin R., Mao M., Khan H., Watt S.R., Watt M.A., Lu Y., Fang X., Tsutsui S., Siddik Z.H., Bast R.C., Mills G.B. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin. Cancer Res. 1999, 5:4308-4318.
7. Goetzl E.J., Dolezalova H., Kong Y., Hu Y.-L., Jaffe R.B., Kalli K.R., Conover C.A. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 1999, 59:5370-5375.
8. Sutphen R., Xu Y., Wilbanks G.D., Fiorica J., Grendys E.C., LaPolla J.P., Arango H., Hoffman M.S., Martino M., Wakeley K., Griffin D., Blanco R.W., Cantor A.B., Xiao Y.J., Krischer J.P. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1185-1191.
9. Gerrard J.M., Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim. Biophys. Acta 1989, 1001:282-285.
10. Eichholtz T., Jalink K., Fahrenfort I., Moolenaar W.H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 1993, 291:677-680.
11. Pustilnik T.B., Estrella V., Wiener J.R., Mao M., Eder A., Watt M.A., Bast R.C., Mills G.B. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin. Cancer Res. 1999, 5:3704-3710.
12. Shida D., Kitayama J., Yamaguchi H., Okaji Y., Tsuno N.H., Watanabe T., Takuwa Y., Nagawa H. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 2003, 63:1706-1711.
13. Schulte K.M., Beyer A., Kohrer K., Oberhauser S., Roher H.D. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. J. Int. Cancer 2001, 92:249-256.
14. Kitayama J., Shida D., Sako A., Ishikawa M., Hama K., Aoki J., Arai H., Nagawa H. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 2004, 6:R640-R646.
15. Shida D., Watanabe T., Aoki J., Hama K., Kitayama J., Sonoda H., Kishi Y., Yamaguchi H., Sasaki S., Sako A., Konishi T., Arai H., Nagawa H. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab. Invest. 2004, 84:1352-1362.
16. Shimomura Y., Wajid M., Ishii Y., Shapiro L., Petukhova L., Gordon D., Christiano A.M. Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nat. Genet. 2008, 40:335-339.
17. Khan S., Habib R., Mir H., Umm e K., Naz G., Ayub M., Shafique S., Yamin T., Ali N., Basit S., Wasif N., Kamran-Ul-Hassan Naqvi S., Ali G., Wali A., Ansar M., Ahmad W. Mutations in the LPAR6 and LIPH genes underlie autosomal recessive hypotrichosis/woolly hair in 17 consanguineous families from Pakistan. Clin. Exp. Dermatol. 2011, 36:652-654.
18. Majewski T., Lee S., Jeong J., Yoon D.S., Kram A., Kim M.S., Tuziak T., Bondaruk J., Lee S., Park W.S., Tang K.S., Chung W., Shen L., Ahmed S.S., Johnston D.A., Grossman H.B., Dinney C.P., Zhou J.H., Harris R.A., Snyder C., Filipek S., Narod S.A., Watson P., Lynch H.T., Gazdar A., Bar-Eli M., Wu X.F., McConkey D.J., Baggerly K., Issa J.P., Benedict W.F., Scherer S.E., Czerniak B. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab. Invest. 2008, 88:694-721.
19. Lee S., Jeong J., Majewski T., Scherer S.E., Kim M.S., Tuziak T., Tang K.S., Baggerly K., Grossman H.B., Zhou J.H., Shen L., Bondaruk J., Ahmed S.S., Samanta S., Spiess P., Wu X., Filipek S., McConkey D., Bar-Eli M., Issa J.P., Benedict W.F., Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc. Natl. Acad. Sci. USA 2007, 104:13732-13737.
20. Hama K., Aoki J., Fukaya M., Kishi Y., Sakai T., Suzuki R., Ohta H., Yamori T., Watanabe M., Chun J., Arai H. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J. Biol. Chem. 2004, 279:17634-17639.
21. Shida D., Kitayama J., Yamaguchi H., Hama K., Aoki J., Arai H., Yamashita H., Mori K., Sako A., Konishi T., Watanabe T., Sakai T., Suzuki R., Ohta H., Takuwa Y., Nagawa H. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp. Cell Res. 2004, 301:168-178.
22. Boucharaba A., Serre C.M., Guglielmi J., Bordet J.C., Clezardin P., Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA 2006, 103:9643-9648.
23. David M., Ribeiro J., Descotes F., Serre C.M., Barbier M., Murone M., Clezardin P., Peyruchaud O. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int. J. Oncol. 2012, 40:1133-1141.
24. Yu S., Murph M.M., Lu Y., Liu S., Hall H.S., Liu J., Stephens C., Fang X., Mills G.B. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer Inst. 2008, 100:1630-1642.
25. Fishman D.A., Liu Y., Ellerbroek S.M., Stack M.S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 2001, 61:3194-3199.
26. Jeong K.J., Park S.Y., Cho K.H., Sohn J.S., Lee J., Kim Y.K., Kang J., Park C.G., Han J.W., Lee H.Y. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 2012, 31:4279-4289.
27. Park S.Y., Jeong K.J., Panupinthu N., Yu S., Lee J., Han J.W., Kim J.M., Lee J.S., Kang J., Park C.G., Mills G.B., Lee H.Y. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 2011, 30:1351-1359.
28. Hope J.M., Wang F.Q., Whyte J.S., Ariztia E.V., Abdalla W., Long K., Fishman D.A. LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol. Oncol. 2009, 112:215-223.
29. Jongsma M., Matas-Rico E., Rzadkowski A., Jalink K., Moolenaar W.H. LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS One 2011, 6:e29260.
30. Lin C.I., Chen C.N., Lin P.W., Chang K.J., Hsieh F.J., Lee H. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3. Biochem. Biophys. Res. Commun. 2007, 363:1001-1008.
31. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
32. Hu Y.L., Tee M.K., Goetzl E.J., Auersperg N., Mills G.B., Ferrara N., Jaffe R.B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 2001, 93:762-768.
33. Fujita T., Miyamoto S., Onoyama I., Sonoda K., Mekada E., Nakano H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003, 192:161-169.
34. Su S.C., Hu X., Kenney P.A., Merrill M.M., Babaian K.N., Zhang X.Y., Maity T., Yang S.F., Lin X., Wood C.G. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin. Cancer Res. 2013, 19:6461-6472.
35. Bachelier R., Confavreux C.B., Peyruchaud O., Croset M., Goehrig D., van der Pluijm G., Clezardin P. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. J. Int. Cancer 2014, 135:1319-1329.
36. Boucharaba A., Guillet B., Menaa F., Hneino M., van Wijnen A.J., Clezardin P., Peyruchaud O. Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol. Res. 2009, 18:173-184.
37. Boucharaba A., Serre C.-M., Gres S., Saulnier-Blache J.S., Bordet J.-C., Guglielmi J., Clezardin P., Peyruchaud O. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 2004, 114:1714-1725.
38. David M., Wannecq E., Descotes F., Jansen S., Deux B., Ribeiro J., Serre C.M., Gres S., Bendriss-Vermare N., Bollen M., Saez S., Aoki J., Saulnier-Blache J.S., Clezardin P., Peyruchaud O. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010, 5:e9741.
39. Peyruchaud O., Leblanc R., David M. Pleiotropic activity of lysophosphatidic acid in bone metastasis. Biochim. Biophys. Acta 2013, 1831:99-104.
40. Gillet J.P., Gottesman M.M. Mechanisms of multidrug resistance in cancer. Methods Mol. Biol. 2010, 596:47-76. (Clifton, N.J.).
41. Fukui R., Kato K., Okabe K., Kitayoshi M., Tanabe E., Fukushima N., Tsujiuchi T. Enhancement of drug resistance by lysophosphatidic acid receptor-3 in mouse mammary tumor FM3A cells. J. Toxicol. Pathol. 2012, 25:225-228.
42. Kiss G.N., Lee S.C., Fells J.I., Liu J., Valentine W.J., Fujiwara Y., Thompson K.E., Yates C.R., Sumegi B., Tigyi G. Mitigation of radiation injury by selective stimulation of the LPA(2) receptor. Biochim. Biophys. Acta 2013, 1831:117-125.
43. Stefan C., Jansen S., Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem. Sci. 2005, 30:542-550.
44. Kawagoe H., Stracke M.L., Nakamura H., Sano K. Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma. Cancer Res. 1997, 57:2516-2521.
45. Hoelzinger D.B., Mariani L., Weis J., Woyke T., Berens T.J., McDonough W.S., Sloan A., Coons S.W., Berens M.E. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005, 7:7-16.
46. Zhang G., Zhao Z., Xu S., Ni L., Wang X. Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin. Med. J. 1999, 112:330-332.
47. Masuda A., Nakamura K., Izutsu K., Igarashi K., Ohkawa R., Jona M., Higashi K., Yokota H., Okudaira S., Kishimoto T., Watanabe T., Koike Y., Ikeda H., Kozai Y., Kurokawa M., Aoki J., Yatomi Y. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br. J. Haematol. 2008, 143:60-70.
48. Stracke M.L., Krutzsch H.C., Unsworth E.J., Arestad A., Cioce V., Schiffmann E., Liotta L.A. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 1992, 267:2524-2529.
49. Stassar M.J., Devitt G., Brosius M., Rinnab L., Prang J., Schradin T., Simon J., Petersen S., Kopp-Schneider A., Zoller M. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br. J. Cancer 2001, 85:1372-1382.
50. Kehlen A., Englert N., Seifert A., Klonisch T., Dralle H., Langner J., Hoang-Vu C. Expression, regulation and function of autotaxin in thyroid carcinomas. J. Int. Cancer 2004, 109:833-838.
51. Yang S.Y., Lee J., Park C.G., Kim S., Hong S., Chung H.C., Min S.K., Han J.W., Lee H.W., Lee H.Y. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis 2002, 19:603-608.
52. Yang Y., Mou L., Liu N., Tsao M.S. Autotaxin expression in non-small-cell lung cancer. Am. J. Respir. Cell Mol. Biol. 1999, 21:216-222.
53. Wu J.M., Xu Y., Skill N.J., Sheng H., Zhao Z., Yu M., Saxena R., Maluccio M.A. Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol. Cancer 2010, 9:71.
54. Black E.J., Clair T., Delrow J., Neiman P., Gillespie D.A. Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene 2004, 23:2357-2366.
55. Dufner-Beattie J., Lemons R.S., Thorburn A. Retinoic acid-induced expression of autotaxin in N-myc-amplified neuroblastoma cells. Mol. Carcinog. 2001, 30:181-189.
56. Chen M., O'Connor K.L. Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 2005, 24:5125-5130.
57. Nam S.W., Clair T., Campo C.K., Lee H.Y., Liotta L.A., Stracke M.L. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000, 19:241-247.
58. Liu S., Umezu-Goto M., Murph M., Lu Y., Liu W., Zhang F., Yu S., Stephens L.C., Cui X., Murrow G., Coombes K., Muller W., Hung M.C., Perou C.M., Lee A.V., Fang X., Mills G.B. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009, 15:539-550.
59. Benesch M.G., Tang X., Maeda T., Ohhata A., Zhao Y.Y., Kok B.P., Dewald J., Hitt M., Curtis J.M., McMullen T.P., Brindley D.N. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 2014, 28:2655-2666.
60. Lu Y., Lemon W., Liu P.Y., Yi Y., Morrison C., Yang P., Sun Z., Szoke J., Gerald W.L., Watson M., Govindan R., You M. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006, 3:e467.
61. Houben A.J., Moolenaar W.H. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 2011, 30:557-565.
62. Nakai Y., Ikeda H., Nakamura K., Kume Y., Fujishiro M., Sasahira N., Hirano K., Isayama H., Tada M., Kawabe T., Komatsu Y., Omata M., Aoki J., Koike K., Yatomi Y. Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin. Biochem. 2011, 44:576-581.
63. Jansen S., Andries M., Vekemans K., Vanbilloen H., Verbruggen A., Bollen M. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett. 2009, 284:216-221.
64. Watanabe N., Ikeda H., Nakamura K., Ohkawa R., Kume Y., Aoki J., Hama K., Okudaira S., Tanaka M., Tomiya T., Yanase M., Tejima K., Nishikawa T., Arai M., Arai H., Omata M., Fujiwara K., Yatomi Y. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J. Clin. Gastroenterol. 2007, 41:616-623.
65. Leblanc R., Lee S.C., David M., Bordet J.C., Norman D.D., Patil R., Miller D., Sahay D., Ribeiro J., Clezardin P., Tigyi G.J., Peyruchaud O. Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood 2014, 124:3141-3150.
66. Fulkerson Z., Wu T., Sunkara M., Kooi C.V., Morris A.J., Smyth S.S. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J. Biol. Chem. 2011, 286:34654-34663.
67. Wu T., Kooi C.V., Shah P., Charnigo R., Huang C., Smyth S.S., Morris A.J. Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J. 2014, 28:861-870.
68. David M., Sahay D., Mege F., Descotes F., Leblanc R., Ribeiro J., Clezardin P., Peyruchaud O. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. PLoS One 2014, 9:e97771.